Profectus BioSciences, Inc is an innovative clinical stage vaccine company dedicated to preventing and treating viral diseases and malaria through the application of its proprietary pDNA and rVSV platform. The company's name, Profectus, translates from Latin to mean "to advance or improve," capturing the company’s approach to advance products that improve the health of patients suffering from viral diseases and malaria.
The company, founded in 2002, focuses on developing vaccines targeting HCV, HPV, HSV, HIV, and malaria. With its headquarters in the United States, Profectus BioSciences aims to make significant strides in biotechnology and healthcare.
Profectus BioSciences received a $4.60M grant investment in December 2015, reflecting investor confidence in the company's promising endeavors. The impressive track record and forward-looking approach make Profectus BioSciences an exciting prospect for venture capital investment. For more information, please visit their website at www.profectusbiosciences.net.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $4.60M | - | 09 Dec 2015 | |
| Grant | $9.50M | - | 31 Oct 2014 | |
| Venture Round | $7.29M | 1 |
|
18 Apr 2014 |
| Debt Financing | $480.00K | - | 21 Mar 2013 | |
| Grant | $5.40M | - | 14 Dec 2011 |
No recent news or press coverage available for Profectus BioSciences, Inc.
We care about your data, and we'd love to use cookies make your experience better.
